Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
March 26, 2024 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva to Present at the UBS Virtual CNS Day
March 11, 2024 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva to Present at the 36th Annual ROTH Conference
March 07, 2024 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
February 20, 2024 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
February 06, 2024 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
January 25, 2024 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that...
Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones
January 04, 2024 08:00 ET
|
Reviva Pharmaceuticals
– Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE) trial, and positive drug-drug interaction data...
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
December 11, 2023 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
November 30, 2023 16:05 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 20, 2023 16:05 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...